View More View Less
  • 1 Semmelweis Egyetem, Általános Orvostudományi Kar, Budapest, Baross u. 23–25., 1083
  • 2 Semmelweis Egyetem, Általános Orvostudományi Kar, Budapest
Open access

Absztrakt:

Az új koronavírus okozta COVID–19-járvány kihívást jelent a szervátültetett betegek ellátását illetően is, ezért lényegesnek tartjuk az ezzel kapcsolatos friss ismeretek megosztását a hazai ellátásban dolgozók számára. Nagyobb esetszámmal májátültetettekről még nincsenek adatok az irodalomban, vesetranszplantáltak esetén azonban a spanyol és a francia adatbázisok 18,6%-os és 13%-os halálozásról számoltak be, ami kissé magasabb az ottani átlagpopulációénál. Tünetmentes esetekben SARS-CoV-2-pozitív PCR-eredmény birtokában nem szükséges a transzplantáltak immunszuppresszív terápiáján változtatni, azonban láz, gastrointestinalis vagy légúti tünetek kialakulását követően a mikofenolsav és mTOR-gátló készítmények elhagyása javasolt, és a kalcineurininhibitorok vérszintjét a legalacsonyabb effektív szintre kell csökkenteni. Tüdőkárosodás észlelését követően vesetranszplantáltak esetében a kalcineurininhibitorokat is le kell állítani, míg a májtranszplantáltak esetében a dózis csökkentése szükséges a fenntartó kortikoszteroid mellett. Ez utóbbi dózisának emelése szükséges hyperinflammatiós szindróma (HIS) kialakulásakor. A HIS terápiás befolyásolására transzplantáltakban is sikerrel lehet alkalmazni az IL1- és IL6-gátló monoklonális antitesteket. Célzott vírusellenes készítmény nem áll rendelkezésre, a legszerencsésebb, ha a beteg bevonható a remdesivir vagy a favipiravir klinikai vizsgálatába. A hidroxiklorokin transzplantáltaknak is adható, bár hatékonysága és biztonságossága kérdésessé vált. A lopinavir/ritonavir kombináció a kalcineurininhibitorokkal fennálló súlyos gyógyszerkölcsönhatás miatt nem adható. A SARS-CoV-2 cytopathiás hatása endotheldiszfunkciót okoz, amely prokoaguláns állapot kialakulásához vezet, emellett megváltozik a renin-angiotenzin-aldoszteron rendszer egyensúlya is. Fontos ezért a betegek kezelése során a thrombosisprofilaxis korai elkezdése alacsony molekulasúlyú heparinnal és alacsony dózisú acetilszalicilsavval. Az angiotenzinkonvertálóenzim-gátló (ACEI) és az angiotenzin-II-receptor-antagonista (ARB) terápiára beállított betegek kezelését a COVID–19 miatt nem szabad abbahagyni. Orv Hetil. 2020; 161(32): 1310–1321.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1

    Korsós A, Kupcsulik S, Lovas A, et al. Diagnostic consideration and bedside estimation of the prognosis in COVID-19 patients. [Diagnosztikus lépések és a betegség prognózisának becslése COVID–19-fertőzött betegeken.] Orv Hetil. 2020; 161: 667–671. [Hungarian]

  • 2

    Cho HJ, Koo JW, Roh SK, et al. COVID-19 transmission and blood transfusion: a case report. J Infect Public Health 2020 May 13. . [Epub ahead of print]

    • Crossref
    • Export Citation
  • 3

    Zheng S, Fan J, Yu F, et al. Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January–March 2020: retrospective cohort study. BMJ 2020; 369: m1443.

  • 4

    Ministry of Human Capacities. Handbook of prevention and management of the new coronavirus (SARS-CoV-2) disease (COVID-19). [A 2020. évben azonosított új koronavírus (SARS-CoV-2) okozta fertőzések (COVID–19) megelőzésének és terápiájának kézikönyve.] Emberi Erőforrások Minisztériuma, Budapest, 2020. március 25. Available from: https://mok.hu/public/media/source/kepek/Koronav%C3%ADrus/Magyar%20Koronav%C3%ADrus%20K%C3%A9zik%C3%B6nyv_0328_emmi.pdf [accessed: April 11, 2020]. [Hungarian]

  • 5

    Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395: 1054–1062.

  • 6

    Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020; 382: 1708–1720.

  • 7

    Lovas A, Hankovszky P, Korsós A, et al. Importance of the imaging techniques in the management of COVID-19-infected patients. [A képalkotó diagnosztika jelentősége a COVID–19-fertőzött betegek ellátásában.] Orv Hetil. 2020; 161: 672–677. [Hungarian]

  • 8

    Bhoori S, Rossi RE, Citterio D, et al. COVID-19 in long-term liver transplant patients: preliminary experience from an Italian transplant centre in Lombardy. Lancet Gastroenterol Hepatol. 2020; 5: 532–533.

  • 9

    D’Antiga L. Coronaviruses and immunosuppressed patients: the facts during the third epidemic. Liver Transpl. 2020; 26: 832–834.

  • 10

    Webb GJ, Moon AM, Barnes E, et al. Determining risk factors for mortality in liver transplant patients with COVID-19. Lancet Gastroenterol Hepatol. 2020; 5: 643–644.

  • 11

    Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol. 2020; 5: 428–430.

  • 12

    Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020; 8: 475–481. [Correction: Lancet Respir Med. 2020; 8: e26.]

  • 13

    Pirola CJ, Sookoian S. SARS-CoV-2 virus and liver expression of host receptors: putative mechanisms of liver involvement in COVID-19. Liver Int. 2020 Apr 30. . [Epub ahead of print]

    • Crossref
    • Export Citation
  • 14

    Chau TN, Lee KC, Yao H, et al. SARS-associated viral hepatitis caused by a novel coronavirus: report of three cases. Hepatology 2004; 39: 302–310.

  • 15

    Batlle D, Soler MJ, Sparks MA, et al. Acute kidney injury in COVID-19: emerging evidence of a distinct pathophysiology. J Am Soc Nephrol. 2020 May 4. . [Epub ahead of print]

    • Crossref
    • Export Citation
  • 16

    Su H, Yang M, Wan C, et al. Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney Int. 2020; 98: 219–227.

  • 17

    Farkash EA, Wilson AM, Jentzen JM. Ultrastructural evidence for direct renal infection with SARS-CoV-2. J Am Soc Nephrol. 2020 May 5. . [Epub ahead of print]

    • Crossref
    • Export Citation
  • 18

    Hirsch JS, Ng JH, Ross DW, et al., on behalf of the Northwell COVID-19 Research Consortium; Northwell Nephrology COVID-19 Research Consortium. Acute kidney injury in patients hospitalized with COVID-19. Kidney Int. 2020; 98: 209–218.

  • 19

    Gandolfini I, Delsante M, Fiaccadori E, et al. COVID-19 in kidney transplant recipients. Am J Transplant. 2020 Mar 31. . [Epub ahead of print]

    • Crossref
    • Export Citation
  • 20

    Wang J, Li X, Cao G, et al. COVID-19 in a kidney transplant patient. Eur Urol. 2020; 77: 769–770.

  • 21

    Huang J, Lin H, Wu Y, et al. COVID-19 in posttransplant patients – report of 2 cases. Am J Transplant. 2020 Apr 3. . [Epub ahead of print]

    • Crossref
    • Export Citation
  • 22

    Alberici F, Delbarba E, Manenti C, et al. Management of patients on dialysis and with kidney transplantation during the SARS-CoV-2 (COVID-19) pandemic in Brescia, Italy. Kidney Int Rep. 2020; 5: 580–585.

  • 23

    Trujillo H, Caravaca-Fontán F, Sevillano Á, et al. SARS-CoV-2 infection in hospitalized patients with kidney disease. Kidney Int Rep. 2020; 5: 905–909.

  • 24

    Akalin E, Azzi Y, Bartash R, et al. Covid-19 and kidney transplantation. N Engl J Med. 2020; 382: 2475–2477.

  • 25

    Sánchez-Álvarez JE, Pérez Fontán M, Jiménez Martín C, et al. Status of SARS-CoV-2 infection in patients on renal replacement therapy. Report of the COVID-19 Registry of the Spanish Society of Nephrology (SEN). [Situación de la infección por SARS-CoV-2 en pacientes en tratamiento renal sustitutivo. Informe del Registro COVID-19 de la Sociedad Española de Nefrología (SEN).] Nefrologia 2020; 40: 272–278. [Spanish]

  • 26

    Société Francophone de Transplantation; Société Francophone de Néphrologie Dialyse et Transplantation; Association Française d’Urologie. Reprise de l’activité de greffe rénale adulte en période épidémique de SARS-CoV-2 (Covid-19). Recommandation des sociétés savantes SFT/SFNDT/AFU. Available from: https://www.transplantation-francophone.org/images/public/Reprise_de_lactivite_de_transplantation_renale_adulte_argumentaire_SFT_SFNDT.pdf [accessed: May 14, 2020]. [French]

  • 27

    American Association for the Study of Liver Diseases. Clinical best practice advice for hepatology and liver transplant providers during the COVID-19 pandemic: AASLD expert panel consensus statement. Available from: https://www.aasld.org/sites/default/files/2020-05/AASLD-COVID19-ClinicalInsights-May142020-FINAL-v2.pdf [accessed: May 14, 2020].

  • 28

    British Transplantation Society; The Renal Association. Guidance on the management of transplant recipients diagnosed with or suspected of having COVID19. Updated 24th April 2020. Available from: https://bts.org.uk/wp-content/uploads/2020/04/Clinical-management-of-transplants-and-immunosuppression-updated-24th-April-FINAL.pdf [accessed: April 24, 2020].

  • 29

    López V, Vázquez T, Alonso-Titos J, et al. Recommendations on management of the SARS-CoV-2 coronavirus pandemic (Covid-19) in kidney transplant patients. Nefrologia 2020 Apr 3. . [Epub ahead of print]

    • Crossref
    • Export Citation
  • 30

    Massachusetts General Hospital COVID-19 Treatment Guidance. May 19, 2020 update. (Version 4.0 5/19/2020 6:00PM.) Available from: https://www.massgeneral.org/assets/MGH/pdf/news/coronavirus/mass-general-COVID-19-treatment-guidance.pdf [accessed: May 19, 2020].

  • 31

    Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal. J Heart Lung Transplant. 2020; 39: 405–407.

  • 32

    Ingraham NE, Lotfi-Emran S, Thielen BK, et al. Immunomodulation in COVID-19. Lancet Respir Med. 2020; 8: 544–546.

  • 33

    Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol. 2020; 20: 355–362. [Correction: Nat Rev Immunol. 2020 Jun 2.]

  • 34

    Henry BM, Vikse J, Benoit S, et al. Hyperinflammation and derangement of renin-angiotensin-aldosterone system in COVID-19: a novel hypothesis for clinically suspected hypercoagulopathy and microvascular immunothrombosis. Clin Chim Acta 2020; 507: 167–173.

  • 35

    Zátroch I, Smudla A, Babik B, et al. Procoagulation, hypercoagulation and fibrinolytic “shut down” detected with ClotPro® viscoelastic tests in COVID-19 patients. [Procoagulatio, hypercoagulatio és fibrinolysis „shut down” kimutatása ClotPro® viszkoelasztikus tesztek segítségével COVID–19-betegekben.] Orv Hetil. 2020; 161: 899–907. [Hungarian]

  • 36

    BC Transplant. Clinical guidelines for transplant medications. Revised Jan 2019. AMB.03.007 Rev11. Available from: http://www.transplant.bc.ca/Documents/Health%20Professionals/Clinical%20guidelines/Clinical%20Guidelines%20for%20TRANSPLANT%20MEDICATIONS.pdf [accessed: January 8, 2019].

  • 37

    Kékes E, Nagy J, Kovács T. COVID-19 infection and RAAS inhibitors. [COVID-19-fertőzés és RAAS-gátlók]. Hyperton Nephrol. 2020; 24(1 Klsz): 5–9. [Hungarian]

  • 38

    Statement of the European Society of Hypertension (ESH) on hypertension, renin-angiotensin system (RAS) blockers and COVID-19. April 15th 2020. Available from: https://www.eshonline.org/esh-content/uploads/2020/06/Statement-ESH-on-Hypertension-RAS-Blockers-and-COVID-19-Update-April-15-2020.pdf [accessed: April 15, 2020].

  • 39

    Fábián Á, László I, Juhász M, et al. Pharmacological options in treating SARS-CoV-2 infection/COVID-19. [Farmakoterápiás lehetőségek SARS-CoV-2-fertőzés/COVID–19-betegség esetén.] Orv Hetil. 2020; 161: 685–688. [Hungarian]

  • 40

    Sanders JM, Monogue ML, Jodlowski TZ, et al. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA 2020; 323: 1824–1836.

  • 41

    Scavone C, Brusco S, Bertini M, et al. Current pharmacological treatments for COVID-19: what’s next? Br J Pharmacol. 2020 Apr 24. . [Epub ahead of print]

    • Crossref
    • Export Citation
  • 42

    Du YX, Chen XP. Favipiravir: pharmacokinetics and concerns about clinical trials for 2019-nCoV infection. Clin Pharmacol Ther. 2020 Apr 4. . [Epub ahead of print]

    • Crossref
    • Export Citation
  • 43

    Mulangu S, Dodd LE, Davey RT Jr, et al. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med. 2019; 381: 2293–2303.

  • 44

    Grein J, Ohmagari N, Shin D, et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med. 2020; 382: 2327–2336.

  • 45

    National Institutes of Health. NIH clinical trial shows remdesivir accelerates recovery from advanced COVID-19. Available from: https://www.nih.gov/news-events/news-releases/nih-clinical-trial-shows-remdesivir-accelerates-recovery-advanced-covid-19 [accessed: April 29, 2020].

  • 46

    U.S. Food and Drug Administration. Coronavirus (COVID-19) update: FDA issues emergency use authorization for potential COVID-19 treatment. Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-potential-covid-19-treatment [accessed: May 1, 2020].

  • 47

    Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science 2020; 368: 473–474.

  • 48

    Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci USA 2020; 117: 10970–10975.

  • 49

    Toniati P, Piva S, Cattalini M, et al. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in Brescia, Italy. Autoimmun Rev. 2020; 19: 102568.

  • 50

    Cavalli G, De Luca G, Campochiaro C, et al, Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol. 2020; 2: e325–e331.

 

The author instructions are available in PDF.
Instructions for Authors in Hungarian HERE.

 

Mendeley citation style is available HERE.
  • Impact Factor (2019): 0.497
  • Scimago Journal Rank (2018): 0.176
  • SJR Hirsch-Index (2018): 20
  • SJR Quartile Score (2018): Q3 Medicine (miscellaneous)
  • Impact Factor (2018): 0.564
  • Scimago Journal Rank (2018): 0.193
  • SJR Hirsch-Index (2018): 18
  • SJR Quartile Score (2018): Q3 Medicine (miscellaneous)

Language: Hungarian

Founded in 1857
Publication: Weekly, one volume of 52 issues annually

Senior editors

Editor(s)-in-Chief: Papp Zoltán

Read the professional career of Papp Zoltán HERE.

 

Editorial Board

Click for the Editorial Board

Akadémiai Kiadó
Address: Prielle Kornélia u. 21-35. H-1117 Budapest, Hungary
Phone: (+36 1) 464 8235 ---- Fax: (+36 1) 464 8221
Email: orvosihetilap@akkrt.hu